文献速递消化、代谢与肾脏急症儿科与产科急症

患者特异性方案与基于体重方案治疗急诊科血管闭塞事件的比较

A comparison of the effect of patient-specific versus weight-based protocols to treat vaso-occlusive episodes in the emergency department.
PubMed 文献 · Acad Emerg Med · 2023-11-12
一句话结论急诊血管闭塞危象患者中,患者特异性疼痛方案与基于体重给药方案的疼痛缓解无显著差异,但患者特异性方案组急诊停留时间更短(p=0.008)。

该前瞻性随机对照试验在6个急诊科比较了患者特异性疼痛方案(PSP)与基于体重(WB)的肠外阿片类药物给药方案,用于镰状细胞病血管闭塞危象(VOC)患者。共328例受试者随机化,104例入组,96次就诊有完整数据;因COVID-19影响未能达到目标样本量(目标230例)而提前终止。两组主要结局(疼痛强度评分变化)无显著差异,但PSP组急诊停留时间更短(p=0.008),两组副作用发生率均低。两组疼痛均出现具有临床意义且统计学显著的下降(0-100 mm量表上27 mm)。

要点

  • 在6个急诊科进行的随机对照试验中,PSP组与WB组主要结局(疼痛强度评分变化)无显著差异。
  • PSP组急诊停留时间较WB组更短(p=0.008),但研究因COVID-19提前终止,未达目标样本量230例。
  • 两组疼痛均下降27 mm(0-100 mm量表),具有临床意义和统计学显著性。
  • 两组副作用发生率均低,安全性良好。
  • 排除标准包括:已有PSP排除肠外阿片类镇痛、门诊使用丁丙诺啡或美沙酮、或高度疑似COVID-19。

适用人群与场景

  • 镰状细胞病(SCD)患者,因血管闭塞危象(VOC)就诊于急诊科。
  • 排除标准:已有患者特异性方案排除肠外阿片类镇痛、门诊使用丁丙诺啡或美沙酮、或高度疑似COVID-19。

处置流程与药物剂量

  • 患者特异性疼痛方案(PSP):由SCD提供者撰写方案并存入电子健康记录,供未来急诊就诊使用。
  • 基于体重(WB)的肠外阿片类药物给药方案。
  • 每30分钟评估疼痛强度评分、副作用和安全性,直至入急诊床位后6小时。

研究设计与关键结果

  • 研究类型:前瞻性随机对照试验,在6个急诊科进行;共328例受试者随机化,104例入组(目标230例),96次就诊有完整数据;因COVID-19影响未能达到目标样本量而提前终止。
  • 主要结局:从入急诊空间到离院或6小时疼痛强度评分变化,两组无显著差异。
  • 次要结局:PSP组急诊停留时间更短(p=0.008);两组副作用发生率均低。
  • 两组疼痛均下降27 mm(0-100 mm量表),具有临床意义和统计学显著性。

证据类型、等级与局限

  • 证据类型:前瞻性随机对照试验。
  • 局限:研究因COVID-19影响未能达到目标样本量(目标230例,实际104例入组)而提前终止。

对床旁实践的改变

  • 对于镰状细胞病血管闭塞危象的急诊患者,患者特异性疼痛方案可能缩短急诊停留时间(p=0.008),但疼痛缓解程度与基于体重方案无显著差异。
  • 研究因COVID-19提前终止,未达目标样本量,结果需谨慎解读。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Vaso-occlusive crises (VOCs) cause debilitating pain and are a common cause of emergency department (ED) visits, for people with sickle cell disease (SCD). Strategies for achieving optimal pain control vary widely despite evidence-based guidelines. We tested existing guidelines and hypothesized that a patient-specific pain protocol (PSP) written by their SCD provider may be more effective than weight-based (WB) dosing of parenteral opiate medication, in relieving pain.

METHODS: This study was a prospective, randomized controlled trial comparing a PSP versus WB protocol for patients presenting with VOCs to six EDs. Patients were randomized to a PSP or WB protocol prior to an ED visit. The SCD provider wrote their protocol and placed it in the electronic health record for future ED visits with VOC exclusion criteria that included preexisting PSP excluding parenteral opioid analgesia or outpatient use of buprenorphine or methadone or highly suspected for COVID-19. Pain intensity scores, side effects, and safety were obtained every 30 min for up to 6 h post-ED bed placement. The primary outcome was change in pain intensity score from placement in an ED space to disposition or 6 h.

RESULTS: A total of 328 subjects were randomized; 104 participants enrolled (ED visit, target n = 230) with complete data for 96 visits. The study was unable to reach the target sample size and stopped early due to the impact of COVID-19. We found no significant differences between groups in the primary outcome; patients randomized to a PSP had a shorter ED length of stay (p = 0.008), and the prevalence of side effects was low in both groups. Subjects in both groups experienced both a clinically meaningful and a statistically significant decrease in pain (27 mm on a 0- to 100-mm scale).

CONCLUSIONS: We found a shorter ED length of stay for patients assigned to a PSP. Patients in both groups experienced good pain relief without significant side effects.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Tanabe P, Ibemere S, Pierce AE, et al. A comparison of the effect of patient-specific versus weight-based protocols to treat vaso-occlusive episodes in the emergency department. Acad Emerg Med. 2023. PMID: 37731093. doi:10.1111/acem.14805

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。